Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1540 | Fit test Wiki | 1.00 |
| drug1536 | Filtration Test Wiki | 1.00 |
| drug3981 | The standard of care Wiki | 1.00 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D003141 | Communicable Diseases NIH | 0.07 |
| D007239 | Infection NIH | 0.05 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
An Open-label, prospective, randomized, comparative, multiple doses applied in addition to the standard of care treatment of patients with moderate to severe COVID-19 infection
Description: The time of onset of improvement in the patient's clinical condition will be measured following the clinical objective and subjective signs and radiological indicators.
Measure: Time to onset of change in the patient's clinical condition Time: 21 dayDescription: At every examination/evaluation, all AEs, whether noticed by investigators and their associates in the trial, or spontaneously reported by the subjects, or given as answer to direct question, must be evaluated by the investigator and reported on case report forms for AE. AE will be recorded in the e-CRF. Three-degree scale will be used for assessment of AE's severity: mild, moderate, severe.
Measure: Safety and tolerability evaluation - treatment-related adverse events will be assessed by CTCAE Time: 21 dayDescription: To monitor the period of patient's hospitalization
Measure: Length of in-hospital stay Time: 21 dayDescription: To monitor the survival rate during the hospitalization
Measure: Survival rate Time: 21 dayDescription: To monitor the intubation frequency during the hospitalization
Measure: Intubation rate Time: 21 dayDescription: To monitor the levels of proinflammatory markers during the hospitalization (IL-6)
Measure: Proinflammatory markers levels Time: 21 dayAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports